Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide.

Pub Date : 2023-04-01 Epub Date: 2023-07-17 DOI:10.4103/ijabmr.ijabmr_58_23

Shiba Ansari, Madeeha Mudassir, B Vijayalekshmi, Parthaprasad Chattopadhyay

{"title":"Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide.","authors":"Shiba Ansari, Madeeha Mudassir, B Vijayalekshmi, Parthaprasad Chattopadhyay","doi":"10.4103/ijabmr.ijabmr_58_23","DOIUrl":null,"url":null,"abstract":"Background: Chemokine receptor CXCR4 is frequently present in cells of various cancers. Hence, targeted therapy using CXCR4 ligands, such as DV1 peptide, on drug-loaded nanoparticles, has the potential to enhance the efficiency of cancer treatment.Aim: The present study created a CXCR4-targeting drug delivery system using avidin-poly (lactic-co-glycolic acid) (PLGA) nanoparticle surface tagged with biotinylated DV1 peptide ligand.Materials and methods: A double-emulsion solvent evaporation technique was employed to prepare avidin-PLGA nanoparticles and characterized by transmission electron microscopy (TEM) and dynamic light scattering. Uptake was studied by confocal microscopy after incorporating fluorescein isothiocyanate (FITC)-labeled albumin inside the nanoparticles during their synthesis. Peptide-biotin-avidin-PLGA nanoparticles were tested in vitro on CXCR4-expressing U87MG cells. Photomicroscopy was done by a Nikon A1 Confocal Microscope, and pictures were analyzed by Nikon NIS-Elements BR software.Results: Experimental results confirmed the specificity of DV1 peptide-tagged avidin-PLGA nanoparticles for cells expressing CXCR4 receptors. The avidin-PLGA nanoparticles were successfully synthesized and the same was confirmed by tagging them with FITC-labeled biotin.Conclusion: Avidin-PLGA nanoparticle surface tagged with biotinylated DV1 peptide ligand has potential clinical application in the treatment of various cancers as targeted therapy for CXCR4-expressing cancer cells.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/59/IJABMR-13-106.PMC10443452.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijabmr.ijabmr_58_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chemokine receptor CXCR4 is frequently present in cells of various cancers. Hence, targeted therapy using CXCR4 ligands, such as DV1 peptide, on drug-loaded nanoparticles, has the potential to enhance the efficiency of cancer treatment.

Aim: The present study created a CXCR4-targeting drug delivery system using avidin-poly (lactic-co-glycolic acid) (PLGA) nanoparticle surface tagged with biotinylated DV1 peptide ligand.

Materials and methods: A double-emulsion solvent evaporation technique was employed to prepare avidin-PLGA nanoparticles and characterized by transmission electron microscopy (TEM) and dynamic light scattering. Uptake was studied by confocal microscopy after incorporating fluorescein isothiocyanate (FITC)-labeled albumin inside the nanoparticles during their synthesis. Peptide-biotin-avidin-PLGA nanoparticles were tested in vitro on CXCR4-expressing U87MG cells. Photomicroscopy was done by a Nikon A1 Confocal Microscope, and pictures were analyzed by Nikon NIS-Elements BR software.

Results: Experimental results confirmed the specificity of DV1 peptide-tagged avidin-PLGA nanoparticles for cells expressing CXCR4 receptors. The avidin-PLGA nanoparticles were successfully synthesized and the same was confirmed by tagging them with FITC-labeled biotin.

Conclusion: Avidin-PLGA nanoparticle surface tagged with biotinylated DV1 peptide ligand has potential clinical application in the treatment of various cancers as targeted therapy for CXCR4-expressing cancer cells.

Abstract Image

查看原文

用生物素化DV1肽表面修饰的Avidin-poly（丙交酯-共-乙醇酸）纳米粒子靶向表达CXCR4的癌症细胞。

背景：趋化因子受体CXCR4经常存在于各种癌症的细胞中。因此，在药物负载的纳米颗粒上使用CXCR4配体（如DV1肽）的靶向治疗具有提高癌症治疗效率的潜力。目的：本研究使用生物素化DV1肽配体表面标记的抗生物素-聚乳酸-羟基乙酸（PLGA）纳米粒子创建了CXCR4靶向药物递送系统。材料与方法：采用双乳液溶剂蒸发技术制备了抗生物素PLGA纳米颗粒，并用透射电子显微镜（TEM）和动态光散射对其进行了表征。在纳米颗粒合成过程中，将异硫氰酸荧光素（FITC）标记的白蛋白掺入纳米颗粒中，通过共聚焦显微镜研究其吸收情况。肽-生物素-抗生物素-PLGA纳米粒子在表达CXCR4的U87MG细胞上进行体外测试。通过Nikon A1共焦显微镜进行光学显微镜检查，并通过Nikon NIS Elements BR软件分析图片。结果：实验结果证实了DV1肽标记的抗生物素PLGA纳米粒子对表达CXCR4受体的细胞的特异性。成功合成了抗生物素蛋白PLGA纳米颗粒，并通过用FITC标记的生物素标记它们来证实这一点。结论：生物素化DV1肽配体表面标记的Avidin-PLGA纳米粒子作为表达CXCR4的癌症细胞的靶向治疗，在治疗各种癌症方面具有潜在的临床应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文